임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

12건 표시

3상완료· Acute Bronchitis
Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
리드: 유한양행
상세 →NCT07111468
3상모집 중· Parenteral Nutrition
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
리드: 유한양행
상세 →NCT06625957
3상완료· Parenteral Nutrition
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
리드: 유한양행
상세 →NCT06625931
3상완료· Non-Small Cell Lung Cancer
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
리드: 유한양행
상세 →NCT04248829
3상완료· Hypertension and Hyperlipidemia
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
리드: 유한양행
상세 →NCT03103256
3상완료· Hypertension
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
리드: 유한양행
상세 →NCT03067688
3상완료· Peripheral Neuropathic Pain
Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain
리드: 유한양행
상세 →NCT02985216
3상완료· Hypertension
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
리드: 유한양행
상세 →NCT02620163
3상완료· Dyslipidemia
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
리드: 유한양행
상세 →NCT02586129
3상완료· Hyperlipidemia
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
리드: 유한양행
상세 →NCT01914432
3상완료· Seasonal Allergic Rhinitis
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis
리드: 유한양행
상세 →NCT01400828
3상완료· Coronary Artery Disease
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study
협력: 유한양행
상세 →NCT02294643

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.